vs
Side-by-side financial comparison of SOUTHSIDE BANCSHARES INC (SBSI) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $62.8M, roughly 1.1× SOUTHSIDE BANCSHARES INC). SOUTHSIDE BANCSHARES INC runs the higher net margin — 33.4% vs -49.0%, a 82.4% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -4.8%). SOUTHSIDE BANCSHARES INC produced more free cash flow last quarter ($73.5M vs $-84.7M).
Southside Bancshares Inc. is a U.S.-based bank holding company primarily operating in Texas. It offers a full range of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial loans, and wealth management solutions, serving retail customers, small and medium-sized enterprises and local community groups.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SBSI vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.8M | $70.6M |
| Net Profit | $21.0M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 39.4% | -56.7% |
| Net Margin | 33.4% | -49.0% |
| Revenue YoY | -4.8% | 81958.1% |
| Net Profit YoY | -3.7% | 54.9% |
| EPS (diluted) | $0.70 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.8M | — | ||
| Q3 25 | $43.7M | $70.6M | ||
| Q2 25 | $66.4M | — | ||
| Q1 25 | $64.1M | — | ||
| Q4 24 | $66.0M | — | ||
| Q3 24 | $63.6M | — | ||
| Q2 24 | $65.2M | — | ||
| Q1 24 | $63.1M | — |
| Q4 25 | $21.0M | — | ||
| Q3 25 | $4.9M | $-34.6M | ||
| Q2 25 | $21.8M | — | ||
| Q1 25 | $21.5M | — | ||
| Q4 24 | $21.8M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $24.7M | — | ||
| Q1 24 | $21.5M | — |
| Q4 25 | 39.4% | — | ||
| Q3 25 | 11.7% | -56.7% | ||
| Q2 25 | 40.0% | — | ||
| Q1 25 | 40.9% | — | ||
| Q4 24 | 40.1% | — | ||
| Q3 24 | 39.2% | — | ||
| Q2 24 | 45.9% | — | ||
| Q1 24 | 41.4% | — |
| Q4 25 | 33.4% | — | ||
| Q3 25 | 11.2% | -49.0% | ||
| Q2 25 | 32.8% | — | ||
| Q1 25 | 33.6% | — | ||
| Q4 24 | 33.0% | — | ||
| Q3 24 | 32.3% | — | ||
| Q2 24 | 37.9% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | $0.70 | — | ||
| Q3 25 | $0.16 | — | ||
| Q2 25 | $0.72 | — | ||
| Q1 25 | $0.71 | — | ||
| Q4 24 | $0.71 | — | ||
| Q3 24 | $0.68 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $0.71 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $389.8M | $490.9M |
| Total DebtLower is stronger | $300.0M | — |
| Stockholders' EquityBook value | $847.6M | $503.0M |
| Total Assets | $8.5B | $577.1M |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $389.8M | — | ||
| Q3 25 | $466.9M | $490.9M | ||
| Q2 25 | $390.1M | — | ||
| Q1 25 | $431.0M | — | ||
| Q4 24 | $426.2M | — | ||
| Q3 24 | $486.3M | — | ||
| Q2 24 | $452.0M | — | ||
| Q1 24 | $469.4M | — |
| Q4 25 | $300.0M | — | ||
| Q3 25 | $299.9M | — | ||
| Q2 25 | $152.4M | — | ||
| Q1 25 | $152.4M | — | ||
| Q4 24 | $152.3M | — | ||
| Q3 24 | $152.3M | — | ||
| Q2 24 | $152.2M | — | ||
| Q1 24 | $154.2M | — |
| Q4 25 | $847.6M | — | ||
| Q3 25 | $834.9M | $503.0M | ||
| Q2 25 | $807.2M | — | ||
| Q1 25 | $816.6M | — | ||
| Q4 24 | $811.9M | — | ||
| Q3 24 | $805.3M | — | ||
| Q2 24 | $801.0M | — | ||
| Q1 24 | $787.9M | — |
| Q4 25 | $8.5B | — | ||
| Q3 25 | $8.4B | $577.1M | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.5B | — | ||
| Q3 24 | $8.4B | — | ||
| Q2 24 | $8.4B | — | ||
| Q1 24 | $8.4B | — |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.19× | — | ||
| Q1 24 | 0.20× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.8M | $-84.6M |
| Free Cash FlowOCF − Capex | $73.5M | $-84.7M |
| FCF MarginFCF / Revenue | 117.0% | -120.1% |
| Capex IntensityCapex / Revenue | 32.4% | 0.2% |
| Cash ConversionOCF / Net Profit | 4.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $130.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.8M | — | ||
| Q3 25 | $40.2M | $-84.6M | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $23.9M | — | ||
| Q4 24 | $101.8M | — | ||
| Q3 24 | $-11.7M | — | ||
| Q2 24 | $16.5M | — | ||
| Q1 24 | $58.3M | — |
| Q4 25 | $73.5M | — | ||
| Q3 25 | $37.4M | $-84.7M | ||
| Q2 25 | $-2.0M | — | ||
| Q1 25 | $21.5M | — | ||
| Q4 24 | $90.7M | — | ||
| Q3 24 | $-14.2M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $55.7M | — |
| Q4 25 | 117.0% | — | ||
| Q3 25 | 85.5% | -120.1% | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | 33.6% | — | ||
| Q4 24 | 137.4% | — | ||
| Q3 24 | -22.3% | — | ||
| Q2 24 | 23.6% | — | ||
| Q1 24 | 88.4% | — |
| Q4 25 | 32.4% | — | ||
| Q3 25 | 6.5% | 0.2% | ||
| Q2 25 | 12.0% | — | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | 4.47× | — | ||
| Q3 25 | 8.18× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 4.67× | — | ||
| Q3 24 | -0.57× | — | ||
| Q2 24 | 0.67× | — | ||
| Q1 24 | 2.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
